PIK3CA and breast carcinoma: Furthermore, the combination of dovitinib and the dual PI3K/mTOR inhibitor dactolisib (BEZ235) showed strong inhibition of PI3K pathway activation in vitro and in vivo, as well as antitumor activity in FGFR-expressing breast cancer models [48].